Viewing Study NCT03788395


Ignite Creation Date: 2025-12-24 @ 2:04 PM
Ignite Modification Date: 2026-02-02 @ 2:20 PM
Study NCT ID: NCT03788395
Status: COMPLETED
Last Update Posted: 2020-06-09
First Post: 2018-12-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma
Sponsor: Istituto per la Ricerca e l'Innovazione Biomedica
Organization:

Study Overview

Official Title: The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma
Status: COMPLETED
Status Verified Date: 2020-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The management of chronic diseases requires a constant monitoring of treatment adherence, in order to obtain an optimal disease control. However, this is often difficult to achieve, especially in pediatric age.

In this sense, for asthmatic patients treated by Symbicort Turbohaler, "AstraZeneca" developed the "Turbo+", an electronic device attached to the Turbohaler, which allows to feel whether the patient does the inhalation, and to register it on a specific application.

The present randomized trial aims to compare the treatment adherence between asthmatic children/adolescents aged 6-17 years treated with Symbicort Turbohaler plus Turbo+ or Symbicort Turbohaler without Turbo+.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: